OpenOnco · Treatment Plan

Treatment plan — Medullary thyroid carcinoma

PLAN-VAR-MTC-HBV-V1 · v1 · 2026-06-27

Patient

VAR-MTC-HBV · Algorithm: ALGO-MTC-1L

DiagnosisMedullary thyroid carcinoma

MOH / ICD-10C73

ICD-O-38345/3; C73

Clinical significance of mutations (ESCAT)

Tumor-board context — the engine does not use these tiers to rank tracks

✅ Covered biomarkers (matched in KB)

Biomarker	Variant	ESCAT	Evidence	Clinical significance	Drugs	Sources
No clinically actionable variants matched in this profile.

⚠️ Not included in plan

Biomarker	Status
BIO-RET	BIO definition in KB; no ESCAT BMA entry — verify with clinician

Primary current-line option

Standard plan

★ DEFAULT

Indication

IND-MTC-ADVANCED-1L-SELPERCATINIB

Regimen

Selpercatinib monotherapy (advanced/progressive RET-mutant MTC, 1L)

Drugs + NSZU

Selpercatinib (DRUG-SELPERCATINIB) 160 mg PO BID with food (≥50 kg); 120 mg BID (<50 kg) · Continuous, until progression or unacceptable toxicity · PO ✗ Not registered in UA

Reason

Primary current-line option per algorithm ALGO-MTC-1L: selected default was filtered; promoted first remaining current-line track

What NOT to do

Explicit prohibitive rules, each grounded in a regimen / supportive care / contraindication entity

Standard plan (IND-MTC-ADVANCED-1L-SELPERCATINIB)

Do NOT start systemic therapy in asymptomatic, structurally stable, slowly-rising-calcitonin MTC — observe with calcitonin / CEA q3-6 mo + imaging q6-12 mo.
Do NOT use radioactive iodine (RAI) in MTC — parafollicular C-cells do not concentrate iodide; RAI has zero efficacy.
Do NOT skip germline RET testing — ~25% of MTC is hereditary; positive germline drives kindred screening + pheochromocytoma surveillance + prophylactic-thyroidectomy timing in offspring.

Timeline

Treatment timeline — derived from regimen + monitoring schedule

Standard plan

Induction · Selpercatinib monotherapy (advanced/progressive RET-mutant MTC, 1L)

28-day cycles × Continuous until progression

MDT brief

MDT talk tree (2 steps)

#	Owner	Topic	Action
1	infectious_disease_hepatology	Specialist review	Active viral etiology (HCV/HBV) requires parallel antiviral management and reactivation risk assessment.
2	molecular_geneticist	Specialist review	Indication references an actionable genomic biomarker — mutation / target / actionability interpretation needed.

Skills (recommended) — for consideration (2)

Infectious disease / hepatology recommended
Active viral etiology (HCV/HBV) requires parallel antiviral management and reactivation risk assessment.
Molecular geneticist / molecular oncologist recommended
Indication references an actionable genomic biomarker — mutation / target / actionability interpretation needed.

Data quality

Usable with caveats. No critical default-track gap was found, but the MDT should review the listed caveats before final sign-off.

Biomarker coverage: 1/1 known (100%), 0 missing, 0 default-track gaps
Unevaluated RedFlags: RF-MEN2-CONFIRMED-CARRIER, RF-MEN2-FAMILY-HISTORY-SUSPICION, RF-MTC-FRAILTY-AGE, RF-MTC-HIGH-RISK-BIOLOGY, RF-MTC-INFECTION-SCREENING, RF-MTC-ORGAN-DYSFUNCTION, RF-MTC-RET-MUTANT, RF-MTC-TRANSFORMATION-PROGRESSION

Technical MDT skill metadata (2/16 activated in this plan)

All registered virtual specialists. ✓ — activated for this case; ○ — not activated (available for other clinical scenarios).

Specialist	skill_id	Version	Last reviewed	Domain
Cellular therapy specialist (CAR-T)	`cellular_therapy_specialist`	v0.1.0	2026-04-25	cellular_therapy
Clinical pharmacist	`clinical_pharmacist`	v0.1.0	2026-04-25	clinical_pharmacy
Hematologist / oncohematologist	`hematologist`	v0.1.0	2026-04-25	hematology_oncology
Hematopathologist (lymphoma / leukemia / myeloma)	`hematopathologist`	v0.1.0	2026-04-25	hematopathology
Infectious disease / hepatology	`infectious_disease_hepatology`	v0.1.0	2026-04-25	infectious_diseases
Medical oncologist (solid-tumor chemotherapist)	`medical_oncologist`	v0.1.0	2026-04-25	solid_oncology
Molecular geneticist / molecular oncologist	`molecular_geneticist`	v0.1.0	2026-04-25	molecular_oncology
Palliative care	`palliative_care`	v0.1.0	2026-04-25	palliative_care
Pathologist (general)	`pathologist`	v0.1.0	2026-04-25	pathology
Primary care / family physician	`primary_care`	v0.1.0	2026-04-25	primary_care
Psycho-oncologist	`psychologist`	v0.1.0	2026-04-25	psychosocial
Radiation oncologist	`radiation_oncologist`	v0.1.0	2026-04-25	radiation_oncology
Radiologist	`radiologist`	v0.1.0	2026-04-25	diagnostic_imaging
Social worker / case manager	`social_worker_case_manager`	v0.1.0	2026-04-25	psychosocial
Surgical oncologist	`surgical_oncologist`	v0.1.0	2026-04-25	surgical_oncology
Transplant specialist (BMT)	`transplant_specialist`	v0.1.0	2026-04-25	cellular_therapy

Sources cited

SRC-NCCN-THYROID-2025: NCCN Clinical Practice Guidelines — Thyroid Carcinoma (2025.v2)
SRC-ONCOKB: OncoKB — Precision Oncology Knowledge Base (continuous (last verified 2026-04-25))

Experimental options (clinical trials)

Third plan track — open-enrollment trials from ClinicalTrials.gov. Render-time metadata; engine selection is not affected by this block (CHARTER §8.3). Last synced: 2026-06-27.

NCT	Title	Phase	Status	Sponsor	UA	Signals
NCT06444880	Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies	PHASE2	RECRUITING	M.D. Anderson Cancer Center	—	Small N (<50) Single country
NCT03765333	GETNE Registration of Thyroid Cancer	N/A	RECRUITING	Grupo Espanol de Tumores Neuroendocrinos	—	Small N (<50) Single country
NCT07118176	Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers	PHASE1	RECRUITING	Jonsson Comprehensive Cancer Center	—	Phase 1 only Small N (<50) Single country
NCT06161532	Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...	PHASE2	RECRUITING	National Cancer Institute (NCI)	—	Surrogate endpoint only Single country
NCT06814496	Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors	PHASE1 / PHASE2	RECRUITING	University of Arizona	—	Small N (<50) Single country
NCT01660984	Natural History Study of Children and Adults With Medullary Thyroid Cancer	N/A	RECRUITING	National Cancer Institute (NCI)	—	Single country
NCT07383246	CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC	PHASE3	RECRUITING	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	—	Single country
NCT07259304	Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors	N/A	RECRUITING	University of Southern California	—	Single country
NCT05830500	Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma	PHASE4	RECRUITING	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	—	Surrogate endpoint only Single country
NCT03866382	Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors	PHASE2	RECRUITING	National Cancer Institute (NCI)	—	Surrogate endpoint only

Verify recruitment status directly with the trial site. ctgov data can lag behind current UA-site status.

Option availability in Ukraine

Per-track UA registration · NSZU · cost · access pathway. Render-time metadata; engine selection does not depend on these fields (CHARTER §8.3).

Option	UA registration	NSZU	Cost orientation	Access pathway
Standard plan Selpercatinib monotherapy (advanced/progressive RET-mutant MTC, 1L) (REG-SELPERCATINIB-MTC-1L) 1/1 component drug(s) not registered in Ukraine +1	✗ not registered	✗ out-of-pocket	₴-? — verify pathway	not recorded
Trial · NCT06444880 Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT03765333 GETNE Registration of Thyroid Cancer No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT07118176 Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06161532 Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C... No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06814496 Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT01660984 Natural History Study of Children and Adults With Medullary Thyroid Cancer No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT07383246 CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT07259304 Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT05830500 Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT03866382 Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor

Cost information is orientation. Verify with a specific pharmacy / foundation / trial site. Status updated: 2026-06-27.

plan_id: PLAN-VAR-MTC-HBV-V1 | version: 1 | generated: 2026-06-27T09:41:01.932789+00:00

Per FDA non-device CDS positioning (CHARTER §15): Outpatient oncology treatment planning to support tumor-board discussion. Not a medical device; not for autonomous clinical decision-making.

Per FDA non-device CDS positioning (CHARTER §15): Both treatment options below are presented for review. The engine's selection of a 'recommended' default does not constitute a clinical decision. Final treatment selection requires HCP judgment incorporating information not available to the system.

This document is an informational resource supporting tumor-board discussion (per CHARTER §11). It is not a system that makes clinical decisions. Every recommendation must be verified by the treating physician.